Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.

Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
Expert Rev Clin Immunol. 2016 Jun 20;
Authors: Canonica GW, Virchow JC, Zieglmayer P, Ljørring C, Smith IM, Mosbech H
Abstract
INTRODUCTION: In the treatment of house dust mite (HDM) respiratory allergic disease, allergy immunotherapy constitutes an add-on treatment option targeting the underlying immunological mechanisms of allergic disease. However, for the treatment of HDM allergic asthma, the use of subcutaneous allergy immunotherapy (SCIT) has been limited by the risk of systemic adverse events. Thus, sublingually administered allergy immunotherapy (SLIT) has been investigated as a treatment option with an improved tolerability profile that allows for safer treatment of patients with HDM allergic asthma.
AREAS COVERED: In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLIT-tablet, which was recently approved for the treatment of HDM allergic asthma and allergic rhinitis by regulatory authorities in several European countries. Expert Commentary: The SQ HDM SLIT-tablet is the first AIT to be tested prospectively in patients with asthma, and to favorably modify patient relevant endpoints such as requirement for inhaled corticosteroid (ICS) or the time to first exacerbation upon ICS reduction, suggesting that SQ HDM SLIT-tablet treatment may contribute to improving overall asthma control.
PMID...

Source: Expert Review of Clinical Immunology - June 21, 2016 Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research